Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioChem deal

The Laval, Quebec, company and Glaxo Canada Inc. extended their antiviral research agreement for two years to

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE